header logo image


Page 51«..1020..50515253..6070..»

Archive for the ‘Diabetes’ Category

News and announcements from the American Diabetes Association conference – MobiHealthNews

Saturday, June 10th, 2017

Diabetes management is a focus area for a number of digital health companies, and increasingly large medical device companies like Medtronic and Dexcom are turning to smartphone apps and connected devices for their consumer offerings. So its no surprise that at the 77th Scientific Sessions of the American Diabetes Association, which start today, there is a significant health tech presence. We didnt make it out to San Diego ourselves this year, but a lot of the digital health companies have already announced their major news from the conference. As we did last year were rounding up that news here, and well update this piece as more news breaks. Were even including a few news tidbits from this week that werent announced in connection with ADA but impact the diabetes space. Read on for the latest from small startups to major movers and shakers. Dexcom

Its been a big week in the news for the continuous glucose monitor maker. On Monday Dexcom got an important name drop at Apples WWDC: The company will be one of the first to take advantage of Apples addition of native Bluetooth to the Apple Watch. Dexcom has an Apple Watch app at the moment for users of its CGM, but it currently requires the phone to be in range. Now the Watch and the CGM will be able to communicate directly. Then on Wednesday the company announced its long-awaited Android app for Dexcom Share. The Android app just now received FDA clearance, and the company will roll it out this month. At the conference, Dexcom will announce an update to CLARITY, the companys diabetes management software platform. Dexcom is working with the International Diabetes Center (IDC) to incorporate the Ambulatory Glucose Profile, a report developed by IDC. AGP is a standardized way of reporting patient glucose data. AGP reports have been used for several years by physicians, Dr. George Grunberger, chairman of the Grunberger Diabetes Institute, explained in a statement. [It] presents the most relevant statistical and graphical information that would allow clinicians to quickly assess the glucose control of a patient and make meaningful clinical decisions. By having a wider adoption of this report by medical device companies, it allows the information to be agnostic to the manufacturer. AGP can become the EKG report of diabetology where there is one standard glucose report that all clinicians can interpret. One Drop

One Drop Medical, a direct-to-consumer diabetes management system that consists of a lancing device, test strips and a companion app, has expanded its subscription program and launched an Amazon Alexa integration. One Drop subscribers can command the voice assistant to track blood glucose, food and physical activity within the One Drop app, eliminating the need to manually enter any information.

"Accessibility is a foundational value at One Drop," One Drop CEO and founder Jeff Dachis said in a statement. "Now, with new voice and alternative visual interfaces, we are extending our commitment to accessible care with features and programs that allow access to data-driven diabetes care for those with vision challenges, advanced neuropathy, or limited dexterity/mobility, the elderly, caregivers, as well as those challenged by the visual/tactile interfaces associated with smartphones."

Additionally, One Drop is now offering two new specialized diabetes education and coaching programs one on how to deal with the burnout that comes from having a chronic condition, and another for advanced carb counting. The New York-based company will also share results from clinical studies of their system during the ADA conference. Medtronic

Medtronic will present results from several studies, ranging from clinical effectiveness of devices to how machine learning is impacting personalized diabetes management. Scientific presentations will cover insulin pump therapy performance for the MiniMed and SmartGuard systems as well as an update on the performance of SugarIQ, the app Medtronic developed with IBM Watson last year.

The app includes a manual food log and integrates data from Medtronic MiniMed Connect. As users record data about what they eat, when they use insulin, and their blood glucose levels, Watson machine learning generates predictive insights. Medtronic will also delve into notification and engagement strategies, such as in-clinic versus at-home management with email notifications. The company will also host a webcast on June 10 to update their diabetes product pipelines, market outlook and clinical data. T1D Exchange & Admetsys

Boston-based nonprofit T1D Exchange, which is solely focused on spurring innovation and research in type 1 diabetes, is now working withartificial pancreas technology provider Admetsys. The exact terms of the partnership werent disclosed, but T1D Exchange will allocate resources to continue the development of Admetsys Automated Insulin Delivery (AID) system for hospital use. The technology, which has been used in three clinical trials, uses a standard IV to draw a small blood sample every few minutes, measure glucose levels and return the blood back to the patient. From there, Admetsys creates a computational model to direct insulin dosages from syringe pumps. Glooko

Diabetes management company Glooko will detail results from two retrospective studies at ADA. The studies show that the Glooko mobile app led to a decrease in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes. Users of the mobile application also did more blood glucose testing than the control group.The drop in average blood glucose was 3.54 percent. App users were 4.38 percent less likely to experience hyperglycemic events. We are thrilled to see this additional clinical evidence that shows the positive impact Glooko can have on people with diabetes, Rick Altinger, CEO of Glooko, said in a statement. Glookos mission has always been to improve the clinical outcomes for people with diabetes by making diabetes management easier through digital tools. Our user satisfaction rates coupled with this clinical evidence adds credence to the investments that digital health companies have been making to improve the lives of people with chronic diseases. Ascensia & Voluntis Ascensia, a business unit created last year when Panasonic Healthcare Holdings acquired Bayer Diabetes Care, is now working with Paris, France-based app maker Voluntis. Ascensia makes the Contour Next One and Contour Next Link, a pair of connected glucometers that received FDA clearance last year, and Voluntis will develop an app called the Insulia Diabetes Management Companion for people with type 2 diabetes. The glucometers will connect via Bluetooth to the app, allowing blood glucose readings to be used to calculate insulin dosing.

Type 2 diabetes is a complex condition, especially for people using insulin therapy as part of their management. Were excited to be working together with Voluntis to empower people with Type 2 diabetes by helping them to better manage their insulin treatment, Ascensia CEO Michael Kloss said in a statement. This partnership helps us move further towards our ambition of providing integrated diabetes management, which we see as the future. It is our first partnership in the area of medication management, which is a critical component of integrated diabetes management, and we see Voluntis as a key partner in helping to deliver this goal.

DarioHealth

Israel-based smartphone-connected glucometer company DarioHealth isnt announcing data or new features at ATA but will announce a new social initiative called DarioCares. DarioHealth will donate a portion of its proceeds to charitable and nonprofit organizations working in the field of diabetes. "The ADA conference is one of the biggest annual events in the diabetes industry, Chairman and CEO Erez Raphael said in a statement. Many NGOs will be there and we look forward to strengthening our relationships with them and raising diabetes awareness. Furthermore, DarioCares is an excellent chance to play an active role with leading organizations that are driving change for people with diabetes. This is a win-win opportunity where we can make a significant contribution to the diabetes community."

Go here to read the rest:
News and announcements from the American Diabetes Association conference - MobiHealthNews

Read More...

Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi – FierceBiotech

Saturday, June 10th, 2017

Lexicon Pharmaceuticals has posted upbeat data from another phase 3 trial of its Sanofi-partnered dual SGLT1 and SGLT2 inhibitor sotagliflozin. More patients in the treatment arm hit an established target for glycemic control than did in the control cohort, resulting in Lexicon chalking up its third phase 3 success for the diabetes tablet.

The latest trial enrolled 1,402 patients with type 1 diabetes and randomized them to receive either sotagliflozin or placebo. Going into the study the subjects had A1C levels ranging from 7% to 11%. Diabetes associations recommend that patients reduce their A1Clevels to below 7%. A1C is a marker that gives an average blood glucose level. The phase 3 trial assessed the proportion of participants in the sotagliflozin and placebo arms whose A1C levels fell to below 7% over 24 weeks of treatment.

Lexicon said the trial linked sotagliflozin to a statistically-significant improvement in the proportion of patients who met the A1C target. The finding adds to evidence that sotagliflozin helps patients with Type 1 diabetes to control their glucose levels.

Exactly how positive the data are is unclear. In the top-line release Lexicon said the trial met its primary endpoint but provided no details about what proportion of patients in each arm saw their A1C levels fall to below 7%. That datapoint will go some way to showing whether sotagliflozin can go beyond beating the placebo and establish itself as an effective treatment for type 1 diabetics.

The FDA and other regulators have already approved inhibitors of SGLT2, one of the targets hit by sotagliflozin, for use in type 2 diabetics. AstraZeneca and Bristol-Myers Squibbs Farxiga, Boehringer Ingelheim and Eli Lillys Jardiance and Johnson & Johnsons Invokana all compete for this niche.

Lexicon thinks sotagliflozin can improve on these existing therapies by also hitting SGLT1, which mediates the absorption of glucose in the intestines. SGLT2 plays a similar role in the kidneys.

Sanofi identified sotagliflozin as a way to enter and disrupt the nascent market for SGLT2 inhibitors in 2015, prompting it to pay $300 million upfront and up to $1.4 billion in milestones for the global license to the experimental drug. And with sotagliflozin having now come through three phase 3 trialsthe first two of which assessed the change in A1C from baselineit is nearing the day on which it can start recouping some of its outlay.

We look forward to pursuing regulatory submissions for the treatment of type 1 worldwide, Sanofi SVP Jorge Insuasty said in a statement.

Sanofi plans to pursue approvals of sotagliflozin in type 1 diabetes while developing the drug for use by people with the type 2 form of the condition. The French Big Pharma is running three phase 3 trials to assess the effect of sotagliflozin on the A1C levels of patients with type 2 diabetes. Sanofi expects to complete the trials in 2018 and 2019.

Continued here:
Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi - FierceBiotech

Read More...

WSU gets $3 million NIH grant for improving diabetes care in youth – Crain’s Detroit Business

Saturday, June 10th, 2017

Wayne State University has received a $3.05 million grant from the National Institute of Health for a five-year trial focused on helping parents and other caretakers assist diabetic adolescents to complete their daily care.

The trial is aimed at African-American young people diagnosed with Type 1 diabetes, because they are considered to be at higher risk for poor diabetes management, according to Wayne State's website.

The five-year trial will study a computer-delivered intervention during doctor visits that reminds and motivates parents to stay involved in their child's care, the university said in a statement. During visits to the clinic, caretakers will be given a tablet on which an avatar will take them through a sort of multimedia course that includes informational video clips, testimonials, motivational content and goal-setting strategies. Test trials have already been conducted and indicate that the intervention is effective.

"Research has shown that maintaining high levels of parental involvement and supervision of daily diabetes care is a critical predictor of youth diabetes management," said Deborah Ellis, Ph.D., professor of family medicine and public health sciences in Wayne State's School of Medicine. "However, physicians do not always have time to discuss parenting behaviors during busy clinic visits."

It will be rolled out in October at the Children's Hospital of Michigan as well as three sites in Chicago, Ellis said. Between 200 and 250 African-American adolescents will be included in this trial.

Go here to read the rest:
WSU gets $3 million NIH grant for improving diabetes care in youth - Crain's Detroit Business

Read More...

‘Alexa, what’s my blood sugar level and how much insulin should I take?’ – Los Angeles Times

Saturday, June 10th, 2017

Its become a punchline in the tech industry that every start-up is out to change the world. When it comes to medical technology, however, some of the biggest names in Silicon Valley are poised to do just that.

Apple, Google and Amazon have announced or are reported to be developing cutting-edge technologies for managing diabetes, one of the fastest-growing chronic illnesses, affecting more than 420 million people worldwide.

Experts say were at the dawn of a new era of personal technology for a variety of chronic conditions, including diabetes, heart disease and hypertension.

It really isnt a surprise youd see companies like Apple and Google focusing on this, said Mike Matson, a senior analyst at the investment firm Needham & Co. Theyre always looking for new opportunities for growth and healthcare is a big market.

Managing a chronic condition can depend on easy access to data, he said. If youre a Google or Apple, you know how to manage data.

The latest diabetes-related tech endeavor to be announced is the Alexa Diabetes Challenge, which focuses on finding ways for the Amazon Echo smart speaker and its Alexa digital assistant to assist people with Type 2 diabetes in living healthier lives.

Type 2 is by far the most common form of diabetes, frequently associated with obesity. Roughly 95% of the nearly 30 million Americans with diabetes are Type 2.

The Alexa challenge features a $125,000 grand prize for whoever comes up with the best diabetes app for the Amazon Echo, as well as $25,000 each for up to five finalists. Funding is being provided by the drug company Merck, manufacturer of the Type 2 meds Januvia and Janumet.

Not surprisingly for the tech industry, the contest boasts a very fast pace. It was announced in April. The deadline for submissions was last month. Finalists will be announced in July. Demos of selected apps will be conducted in September and a grand prize winner will be announced in October.

Its thus entirely possible that people with diabetes may be using some of these apps by the end of the year. An Amazon spokeswoman declined to comment.

Theres so much information for diabetes management available, said Sara Holoubek, chief executive of Luminary Labs, a New York consulting firm thats organizing the Alexa Diabetes Challenge on behalf of Merck and Amazon. So why is it still so hard to get that information? Maybe we can change that.

Alexas voice control is the key. Whereas someone newly diagnosed with Type 2 diabetes might not know where to start in researching and managing the disease, being able to ask Alexa basic questions may help get people on the right track.

What can I eat? How much exercise should I get? Holoubek said, citing some of the unknowns that suddenly arise with a diabetes diagnosis. Normally youd ask your endocrinologist or diabetes educator. Alexa could be like having an educator in your home.

But thats just a start. Holoubek said Merck and Amazon envision a networked household that incorporates various smart devices. For example, a person with Type 2 diabetes might weigh himself on a smart scale, which would transmit data to the Echo. The persons blood-glucose monitor would do likewise.

Now imagine if the person asks Alexa if it would be OK to eat some potato chips. Alexa theoretically would be able to calculate the effect this could have on his or her blood sugar. The system would be able to suggest how much activity would be needed to balance things out or, better still, come up with a more healthful snack.

I have Type 1 diabetes the autoimmune form that requires daily insulin injections and managing the disease is a full-time job. I already have some very cool gizmos. I wear a glucose sensor on my torso that sends data to my iPhone, which in turn feeds my blood sugar level to my Pebble smartwatch for easy viewing.

I have an Amazon Echo at home. It would be awesome if I could simply ask Alexa what my blood sugar is if Im puttering around the house without my watch on, or if Im in any danger of my sugar level crashing.

How great would it be if I could ask Alexa how many carbs are in a plate of spaghetti carbonara? Or even have Alexa calculate my insulin dose before a meal?

To be sure, theres much testing to be done and federal approvals to be obtained before such systems are handling anything like that. But the Alexa Diabetes Challenge offers a clear indication that the tech industry is pushing boundaries.

Apple reportedly is busy on this front as well, but, as usual, the company is keeping its cards close to the vest.

According to recent, anonymously sourced reports, Apple is devoting significant resources, and big bucks, to giving its Apple Watch the ability to monitor blood sugar without a sensor being inserted under the skin (such as the one I use).

Others have tried and failed to accomplish this feat, so if Apple can pull it off, this would represent a huge breakthrough in diabetes care.

The company reportedly has dozens of biomedical researchers trying to measure blood sugar using optical sensors, perhaps implanted within the band of the Apple Watch. The sensors would shine a light through the skin that would provide readings in a painless, noninvasive fashion.

CNBC reported last month that Apple Chief Executive Tim Cook was spotted wearing a prototype glucose-tracker with his Apple Watch. As best as I can tell, Cook doesnt have diabetes, so hes apparently been using himself as a guinea pig to see how well his companys technology responds to different foods he eats.

No one at Apple got back to me.

For its part, Googles parent company, Alphabet, announced last year that its life-sciences subsidiary, Verily, was partnering with the French drug company Sanofi on a $500-million joint venture aimed at improving diabetes care. Verily has a separate partnership with the British drugmaker GlaxoSmithKline.

Among the various technologies Verily is pursuing is a smart contact lens that would monitor blood sugar levels. Its being developed in conjunction with the Swiss drug company Novartis.

Like Apple and Amazon, Google clammed up when I got in touch.

Read more:
'Alexa, what's my blood sugar level and how much insulin should I take?' - Los Angeles Times

Read More...

Diabetes drugs linked to higher risk for rare but deadly complication … – CBS News

Saturday, June 10th, 2017

A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns.

SGLT2 inhibitors include prescription medications such as canagliflozin, dapagliflozin and empagliflozin. Brand names are Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance and Glyxambi.

These drugs first became available in 2013, but in 2015 the U.S. Food and Drug Administration issued a warning about an increased risk for diabetic ketoacidosis when SGLT2 inhibitors are used.

The condition typically occurs in people with type 1 diabetes. And while it is uncommon in people with type 2 diabetes, case reports have shown it can occur with type 2 disease, according to the study authors.

Play Video

Some diabetes patients are begging doctors for free samples of life-saving insulin because of costs. Between 2002 and 2013, the price of insulin ...

Ketoacidosis can cause vomiting, abdominal pain, shortness of breath and swelling in the brain. Left untreated, the condition can be fatal, the researchers said.

The new study "essentially confirms what doctors had already suspected," said diabetes expert Dr. Stanislaw Klek, an endocrinologist at NYU Winthrop Hospital in Mineola, N.Y.

"Fortunately, the rate of diabetic ketoacidosis is still very low and should not prevent the usage of this medication class," he added. "It is important to be aware of this potential complication and monitor for symptoms of diabetic ketoacidosis, particularly during periods of illness."

In the new study, researchers at Brigham and Women's Hospital in Boston analyzed data from 40,000 people with type 2 diabetes. They found that those taking SGLT2 inhibitors were twice as likely to develop diabetic ketoacidosis than those taking another class of diabetes drugs called DPP4 inhibitors (drugs such as Januvia and Onglyza).

Still, the risk to any one patient remains very slim, the researchers stressed. They estimated that among patients taking an SGLT2 inhibitor, only about 1 in every 1,000 patients would develop ketoacidosis.

Play Video

A new World Health Organization report says that cases of diabetes have skyrocketed, quadrupling from 108 million worldwide in 1980 to over 420 m...

The findings were published June 8 in theNew England Journal of Medicine.

Even though diabetic ketoacidosis is uncommon, doctors need to closely monitor type 2 diabetes patients for signs and symptoms of the complication, said study author Dr. Michael Fralick. He's from Brigham and Women's division of pharmacoepidemiology and pharmacoeconomics.

"This is a side effect that's usually seen in patients with type 1 diabetes mellitus -- not type 2 -- so doctors are not 'on the lookout' for it," Fralick said in a hospital news release. "That means that the risk of this side effect might actually be even higher than what we found due to misdiagnosis/under-recording."

Dr. Minisha Sood is an endocrinologist at Lenox Hill Hospital in New York City. Reviewing the findings, she explained that SGLT2 inhibitors "have been a welcome addition to the arsenal of glucose [blood sugar]-lowering medications. They lower blood glucose by increasing the amount of glucose eliminated through the urine."

But the drugs may interfere with levels of a particular hormone, glucagon, which in turn leads to an unhealthy rise in acids called ketones. "When ketone acids build up in the system, this can lead to diabetic ketoacidosis," Sood explained.

She agreed that patients and doctors should be alert to the rare but potential risk for diabetic ketoacidosis, especially in the early weeks after a person starts taking an SLGT2 inhibitor.

But Sood believes the study findings are not reason for patients to immediately switch to another form of diabetes medication.

"SLGT2 inhibitors work extremely well to control diabetes [and they have the added benefit of lowering blood pressure and weight as well] so the benefits definitely outweigh the risks of therapy," she said.

Read more:
Diabetes drugs linked to higher risk for rare but deadly complication ... - CBS News

Read More...

Month-Long Diabetes Control Possible with New Injection | GEN – Genetic Engineering & Biotechnology News

Tuesday, June 6th, 2017

The daily or once-weekly insulin shotnecessary for the control of type 2 diabetescould be replaced by a twice- or even once-a-month shot. A new, longer-lasting injectable formulation has been developed that combines a familiar diabetes-control molecule, glucagon-like peptide-1 (GLP1), with a heat-sensitive elastin-like polypeptide (ELP). Once a solution containing the GLP1ELP combo passes through a standard needle and penetrates the skin, it reacts to body heat, forming a biodegradable gel-like depot that slowly releases the drug as it dissolves.

The novel drug-delivery mechanism was developed by scientists based at Duke University, who assert that it could be used to enhance therapeutic outcomes by eliminating peak-and-valley pharmacokinetics and improving overall safety and tolerability. The scientists, led by Ashutosh Chilkoti, Ph.D., chair of the department of biomedical engineering at Duke, suggest that their work could be broadly applicable; that is, it could improve the pharmacological performance of peptides and protein therapeutics besides GLP1.

Details of the work appeared June 5 in the journal Nature Biomedical Engineering, in an article entitled One-Week Glucose Control via Zero-Order Release Kinetics from an Injectable Depot of Glucagon-Like Peptide-1 Fused to a Thermosensitive Biopolymer. The one week indicated in the title refers to the drug depots performance in mice. Glucose control, the scientists found, was more durable in rhesus monkeys, and even longer glucose control, the scientists suggested, could be achieved in humans, since humans have slower metabolisms than mice or monkeys.

A subcutaneous depot formed after a single injection of GLP1 recombinantly fused to a thermosensitive elastin-like polypeptide results in zero-order release kinetics and circulation times of up to 10 days in mice and 17 days in monkeys, the authors of the article indicated. The optimized pharmacokinetics lead to 10 days of glycaemic control in three different mouse models of diabetes, as well as the reduction of glycosylated haemoglobin levels and weight gain in ob/ob mice treated once weekly for 8 weeks.

Many current treatments for type 2 diabetes use GLP1, a signaling molecule that causes the pancreas to release insulin to control blood sugar. However, this peptide has a short half-life and is cleared from the body quickly.

To make treatments last longer, researchers have previously fused GLP1 with synthetic microspheres and biomolecules like antibodies, making them active for 2 to 3 days in mice and up to a week in humans. Currently, the longest-acting glucose control treatment on the market, dulaglutide, requires a once-weekly injection, while standard insulin therapies often have to be injected twice or more every day. Despite improvements such as these, many treatments don't include a mechanism to control the rate of the peptide's release, and treatment effectiveness can plateau after prolonged use.

The Duke researchers persisted with their ongoing experiments, which focused on thermosensitive delivery biopolymers. By varying the design of their delivery biopolymers at the molecular level, they found a sweet spot that maximized the duration of the drug's delivery from a single injection, noted Dr. Chilkoti. "By doing so, he continued, we managed to triple the duration of this short-acting drug for type 2 diabetes, outperforming other competing designs."

Building upon their previous work with the drug and delivery system, researchers in the Dr. Chilkotis laboratory optimized their solution to regulate glucose levels in mice for 10 days after a single injection, up from the previous standard of 2 to 3 days.

In further tests, the Duke team found that the optimized formulation improved glucose control in rhesus monkeys for more than 14 days after a single injection, while also releasing the drug at a constant rate for the duration of the trial.

"What's exciting about this work was our ability to demonstrate that the drug could last over 2 weeks in nonhuman primates," remarked Kelli Luginbuhl, a Ph.D. student in Dr. Chilkotis laboratory and co-author of the study. "Because our metabolism is slower than monkeys and mice, the treatment should theoretically last even longer in humans, so our hope is that this will be the first biweekly or once-a-month formulation for people with type 2 diabetes."

Despite a variety of treatment options, managing type 2 diabetes still poses a problem. Patients don't always reach their glycemic targets, and adherence to a treatment plan that relies on frequent, meal-specific dosing leaves room for human error. By limiting the number of injections a person will need to control their glucose levels, the researchers hope this new tool will improve treatment options for the disease.

The researchers now plan to study the immune response to repeated injections and test the material with other animal models. They are also considering additional applications for this controlled-release system, such as delivering pain medication.

Dr. Chilkoti also indicated that because the drug is synthesized inside Escherichia coli bacterial cultures instead of mammalian cells, it is cheaper and faster to produce, making it a potential target for use in developing countries once it's commercialized.

According to a report issued last year by Grand View Research, the global insulin market is expected to reach $53.04 billion by 2022. Grand View anticipates that the most lucrative segment will consist of long-acting analogs. The segments high growth rate, estimated at 15.0%/year, is accounted for by fast-selling products such as Lantus by Sanofi Aventis. Moreover, the addition of new products such as Novo Nordisks Tresiba ultra-long-acting analog is expected to further drive segment growth. Tresiba is administered subcutaneously once daily at any time of day. Even longer-lasting formulations, such as those contemplated by Dr. Chilkotis team, may contribute to yet more growth in the segment.

Read more:
Month-Long Diabetes Control Possible with New Injection | GEN - Genetic Engineering & Biotechnology News

Read More...

Griffin to hosts talks on diabetes – CT Post

Tuesday, June 6th, 2017

Photo: Contributed / Contributed

Griffin to hosts talks on diabetes

The Diabetes Education & Support Group at Griffin Hospital will host two free presentations on managing diabetes during the summer holidays on Tuesdau, June 13 at 2:30 p.m. and 6:30 p.m. at the hospital, 130 Division St., Derby.

Certified Diabetes Educator Mary Swansiger will lead a discussion on managing diabetes during holidays, vacation and special events during the summer, including meal planning and strategies for making the summer happier and healthier.

Both presentations will be in Childbirth Education Classroom A. There will be free valet parking for the 2:30 p.m. presentation.

The Diabetes Education & Support Group meets September through June on the second Tuesday of each month to discuss the management of diabetes, its challenges, and day-to-day dietary concerns. Individuals with diabetes and their caregivers are welcome to attend.

No registration is required. For more information, call 203-732-1137.

See more here:
Griffin to hosts talks on diabetes - CT Post

Read More...

Diabetes Study in Indiana – MyWabashValley

Tuesday, June 6th, 2017

Indianapolis, IN - INDIANAPOLIS (WISH) From awareness, to education, Indiana lawmakers will soon study diabetes. And it's a personal fight for the Indiana lawmaker spearheading the committee.

For millions of Americans, a quick prick, and sugar reading, is a daily routine. But it's something State Representative Vanessa Summers (D-Indianapolis) would like to see go away. "It's just an unnecessary disease that has grown rapid and is at epidemic portions in our country, and especially in Indiana, State Rep. Summers said.

A disease the American Diabetes Association said impacts nearly 30 million Americans by attacking cells and how bodies produce insulin. To fix this problem, Representative Summers is behind a state study. "It's time to put a face and a name, and action to a condition that is treatable, State Rep. Summers said.

The Indiana Department of Health said more than half a million Hoosiers suffer from diabetes. Nearly 300,000 may not know they have it, and it's the seventh leading cause of death across the state.

A problem representative Summers knows well, because she's had the disease for a decade. "I started out with an A1C of 13. Your A1C should be under 6, State Rep. Summers said. A disease that's hit her family hard. "I've had one cousin to die, State Rep. Summers said. He had a foot amputated, and then he died from complications of diabetes."

To save her life, she's made major changes, including her diet, and teaching others as well. "They just have got to eat right, State Rep. Summers said. They've got to rainbow their colors. You need red, green, purple, yellow."

She's gone from four shots a day, to one. A success story she hopes will inspire her fellow lawmakers, and other Hoosiers as they tackle this issue because she knows how tempting it can be to veer off course.

Sometimes I take a bite because I'm human, State Rep. Summers said. I want to taste that cake."

The study committee was announced about a week ago, but it may take some time before the group may not meet until later this summer. Lawmakers use these off-season meetings to learn information that can help them draft bills for when the 2018 session starts.

See the rest here:
Diabetes Study in Indiana - MyWabashValley

Read More...

Cherokee Nation program benefits pre-diabetes patients – Muskogee Daily Phoenix

Monday, June 5th, 2017

A program sponsored by the Cherokee Nation has been successful in reducing the risk of diabetes in pre-diabetics.

"People with pre-diabetes who lose 7 percent of their body weight through a healthy lifestyle intervention reduce their risk for diabetes by 58 percent," said Tonya Wapskineh, Cherokee Nation diabetes prevention manager.

But those who took metformin, a diabetes medication, reduced their risk by 30 percent.The bottom line is that the healthy lifestyle group reduced their risk for diabetes twice as much as those who were placed on medication, Wapskineh said.

With that success, Wapskineh is looking for more Cherokees who qualify for the program. Some of the qualifications include having a history of gestational diabetes for women, a body mass index of over 24 or a history of diabetes in the family.

While joining the class is voluntary, some are referred by their medical provider. The program's goal is to get everyone to lose 7 percent of their body fat.

"It's kind of a wake-up call for them especially when their doctor tells them they can do something to prevent diabetes," said Karen Bryant, physical activity specialist.

A lot of participants have lost up to four pounds in a couple of weeks just by cutting back and not eating french fries every day.

Classes last a year with the first two months as weekly class, the next four months are bi-weekly classes and the remaining meetings are once a month,Wapskineh said.

Most Cherokees have a diet high in fat and fried foods with little vegetables and fruit, Bryant said. She says their eating habits were learned from childhood.

Participants are not told to stop eating that kind of food.

"Wegive them ways to enjoy these foods by cutting portion sizes, cutting fat out of food and replacing unhealthy cooking oil with healthier ones," Bryant said.

Using this program, one Cherokee man started out at 307 pounds, and a year later he is maintaining 175 pounds, Bryant said.

"When he first started his activity program he could barely get one-quarter around the track, and now he walks every chance he gets and still uses a food journal and that's been about five years ago," she said.

His main success was using a food journal and keeping track of what he ate.

Volunteers have a physical activity goal of 150 minutes per week.

"If they can sing or talk normally and are being active they need to work a little harder. If they can't talk they need to slow it down,"Wapskineh said.

For those who are pretty sedentary, Bryant recommends 15 minutes of walking twice a day and work up to 150 minutes a week. For faster weightloss, 60 minutes of brisk walking a day is recommended.

"From what I've seen through the program is that the more education they receive on how to correct their lifestyle, the more effective it is than going to the doctor and getting a pill,"Wapskineh said.

At the Cherokee Nation Wapskineh said she has actually seen their providers move into preventive medicine and are more supportive of promoting the healthy lifestyle program.

Wapskineh's budget is $400,000 and she would like to see that doubled to possibly establish diabetic prevention centers in all 14 counties within the Cherokee Nation jurisdiction.

"But our work is federally funded and the money is just not there that's just my dream," she said.

Information: (918) 207-3839.

Reach Mark Hughes at (918) 684-2908 or mhughes@muskogeephoenix.com.

What to do

The Cherokee Nation is looking for more Cherokees who qualify for the pre-diabetes program. Some of the qualifications include having a history of gestational diabetes for women, a body mass index of over 24 or a history of diabetes in the family.Information: (918) 207-3839.

More:
Cherokee Nation program benefits pre-diabetes patients - Muskogee Daily Phoenix

Read More...

Usher Missed the Manchester Benefit Concert to Take His Son to Summer Camp – PEOPLE.com

Monday, June 5th, 2017

Usherhas revealed why he was absent from Ariana Grandes One Love Manchester benefit concert on Sunday: it was his sons first day at summer camp for children with diabetes.

The 38-year-old singer shared a post on Instagram Monday explaining why he did not perform in Manchester despite being announced as part of the star-studded lineup.

So happy to see that last nights concert in Manchester proved that love always prevails, he captioned a photo of the stage. I would have loved to be there but it was my sons first day at Camp Kudzu, one of the few summer camps for kids living with diabetes. This was an important day for him and for myself as a proud father.

He concluded his message, Stay strong UK.

The Voicealum has previously spoken out about his 9-year-old son Usher V(aka Cinco)s struggle withtype 1 diabetes and used his platform to advocate fora cure for the disease, which prevents the body from producing insulin.

Achild that every day has to prick himself and has to be cautious of what he eats and also to carry this disorder around that really is the type of bravery that we all aspire to have, Usher told PEOPLE at the 2015JDRFs Promise Ball, which aimed to raise awareness and moneyfor research and a cure.

While hes inspired by his son (with ex Tameka Foster), the I Dont Mind singer says its been hard on him too.

Theres been some difficult moments, he said, but having dealt with it on a daily basis, I have a great deal of understanding of what people have to deal with. Its personal.

Excerpt from:
Usher Missed the Manchester Benefit Concert to Take His Son to Summer Camp - PEOPLE.com

Read More...

A Dilemma for Diabetes Patients: How Low to Push Blood Sugar, and How to Do It? – New York Times

Monday, June 5th, 2017

New York Times
A Dilemma for Diabetes Patients: How Low to Push Blood Sugar, and How to Do It?
New York Times
Some diabetes drugs lower blood sugar, yet somehow can increase the chances of heart attacks and strokes. Other medications have no effect on heart risk, while still others lower the odds of heart disease but may have other drawbacks, like high cost or ...

Read the rest here:
A Dilemma for Diabetes Patients: How Low to Push Blood Sugar, and How to Do It? - New York Times

Read More...

Type 2 diabetes: New biopolymer injection may offer weeks of glucose control – Medical News Today

Monday, June 5th, 2017

Keeping blood glucose levels as close to normal as possible is important for people with type 2 diabetes, as it lowers the risk of serious complications. However, despite a long list of treatment options, patients still struggle with glucose control, especially when working out meal-specific doses. Treatments that cut down on injections are seen as a way to overcome this problem. Now, in a paper in Nature Biomedical Engineering, scientists describe a new biopolymer injection that could potentially replace daily or weekly insulin shots with one that need only be given once or twice per month.

Untreated diabetes results in high levels of blood sugar, or glucose, which in the long-term can lead to blindness, kidney disease, heart disease, stroke, and amputation of lower limbs.

Diabetes arises because of a problem with insulin, which is a hormone that is made in the pancreas and which helps cells to absorb glucose so that they can use it for energy.

In type 1 diabetes, the body does not make enough insulin, while in type 2 diabetes - which accounts for 90 to 95 percent of diabetes cases - it cannot use it properly.

Although the incidence of newly diagnosed diabetes is starting to drop in the United States, it is still a huge public health problem that affects more than 29 million people.

In 2013, the Centers for Disease Control and Prevention (CDC) suggested that diabetes was the seventh leading cause of death in the U.S., and that more than a fifth of the country's healthcare costs are for people diagnosed with diabetes.

In their study paper, biomedical engineers from Duke University in Durham, NC, explain that "despite the long list of treatment options," nearly half of type 2 diabetes cases in the U.S. "are not properly managed."

The researchers suggest that one reason for such a high rate of failure in the management of type 2 diabetes is that patients struggle to keep to treatment regimens, especially when they are required to frequently deal with complicated meal-specific doses.

Another reason they give is that many of the widely used treatments bring unwanted side effects, such as raising the risk of low blood sugar, known as hypoglycemia, or weight gain.

From a drug development point of view, one of the biggest challenges in treating diabetes is that insulin demands in the body are always changing.

In order to address this challenge, there are now treatments for type 2 diabetes that use a new class of drugs called glucagon-like peptide-1 (GLP1) receptor agonists. These drugs use GLP1, a signaling molecule, to trigger insulin release in the pancreas.

Because GLP1 does not last long in the body, drug developers have used various ways to extend its half-life - such as fusing it with various synthetic and biological compounds. These attempts have succeeded in extending the drug's active life in the human body for up to a week.

However, the researchers note that despite this improvement, so far none of the current treatments have solved the problem of the drug's effectiveness gradually decreasing over time.

The new approach that the Duke researchers describe fuses GLP1 with a heat-sensitive biopolymer called elastin-like polypeptide. Held in a solution, the biopolymer drug can be injected into the skin with a normal needle.

Once it is in the bloodstream, the heat of the body causes the biopolymer to form a biodegradable gel that releases the drug slowly and steadily, without the "peaks and troughs" associated with other forms of GLP1 delivery.

Using results from previous work on GLP1 for glucose control, the team tried different molecular designs of the new delivery solution.

They eventually found a design of the biopolymer that could control glucose levels in mice for up to 10 days with a single injection. This was a great improvement on previous attempts, after which the controlled release had only lasted for 2 or 3 days.

In tests on rhesus monkeys, the team found that the optimized formulation resulted in glucose control lasting for more than 14 days from a single injection. Also, the drug was released at a constant rate, without "peaks and troughs," during the whole period.

Senior author Ashutosh Chilkoti, a professor of biomedical engineering at Duke, says that they "managed to triple the duration of this short-acting drug for type 2 diabetes, outperforming other competing designs."

At present, patients using dulaglutide - the longest-lasting controlled release treatment for type 2 diabetes - have to inject themselves once per week. Patients on standard insulin treatments must inject themselves at least twice each day.

The team now plans to test the biopolymer on other animals and investigate how the immune system reacts to repeated injections. They also want to find out how well it performs for the controlled release of drugs in other areas, such as pain management.

"What's exciting about this work was our ability to demonstrate that the drug could last over 2 weeks in non-human primates. Because our metabolism is slower than monkeys and mice, the treatment should theoretically last even longer in humans, so our hope is that this will be the first bi-weekly or once-a-month formulation for people with type 2 diabetes."

First author Kelli Luginbuhl, Ph.D., student at Duke University

Learn how a gut bacteria compound may help to prevent type 2 diabetes.

Here is the original post:
Type 2 diabetes: New biopolymer injection may offer weeks of glucose control - Medical News Today

Read More...

The Real World, Diabetes: As cameras roll, patients seek healing – STAT

Monday, June 5th, 2017

M

ONTEGO BAY, Jamaica The man who boasts ofchanging the face of diabetes spreads his arms out wide, like the Christ the Redeemer statue, but in neon orange shorts and bare feet. He looks earnestly into the rolling camera.

Welcome to Reversed, he intones. Seated behind him are four of his disciples: Americans with type 2 diabetes whove flown to this tropical beach town to participate in a reality TV show marketed as a momentous opportunity to restore their health.Over eight days, theyll learn to exercise and eat right and bare their struggles in cathartic therapy sessions.

Their host, Charles Mattocks, is a smooth-talking, fast-moving entrepreneur, who has leveraged his family fame (his uncle was Bob Marley) and his own medical history (he uses diet and exercise, not insulin, to manage his diabetes) to set himself up as a guru to diabetics everywhere.

In an age where nearly 1 in 10 Americans has diabetes, a disease that can bring a lifetime of painful complications, patients are often desperate for miraculous turnarounds and theres a booming trade in supplements, diets, and self-help books that promise answers. Now, theres a TV show, too.

But Reversed is unlikely to prove anyones salvation.

The show,which will begin airing next month on cable, is at once a vehicle for Mattocks to proselytize his gospel of self-help, a marketing gambit by a pharma company thats running out of money, and a season-long advertisement for a luxury getaway at the sparkling resort where it was filmed.

The carefully choreographed, relentlessly upbeat atmosphere cultivatedunderthe Jamaican sun feels, well, unreal. Back at home, the shows stars like the viewers expected to tune in dont have in-house chefs to cook them healthy meals or mentors toguide them through yoga lessons.

Instead, theyre grappling with the stubborn realities and compounding challenges so common inpatients with chronic disease: deteriorating vision, nerve damage in their feet,congestive heart failure, hypertension, high body fat, the inability to work and even to walk. Just before the show, one of the participantslost her home; two others, a married couple, had been relying on food banks because they hadnt been able to afford to go to a grocery store for months.

Mattocks, the shows executive producer and creator, said he originally imagined Reversedas The Biggest Loser meets diabetes a reference to the long-running weight-loss competition on NBC.

But the participants on Reversed arent competing. Judging from the two days of filming that STAT observed, the show has more in common with the reality TV tradition of putting a bunch of strangers in a house together and seeing what happens. Call it The Real World: Diabetes, featuring burned kale chips, frowned-on cigarette breaks, and one participants dramatic decision to quit the show. (I dont think he was coming here for the right reasons at all, Mattocks told STAT, borrowing the ultimate reality TV insult.)

So it went for the weekof filming, as Mattocks put his cast members through a quirky array of activities:There were massages, just steps from the glittering Caribbean. Trust exercises featuring blindfolds, a basketball, and a banana. Lessons about natural remedies and medicinal plants on a day trip to a nearby farm.

Where are all the new diabetes drugs?

The camera operators scurried on instinct toward any hint of drama or tears. And they didnt always abide by the shows lessons for good health: At lunch one day, for instance, the diabetics ate seasoned vegetablesand sipped water while some crew members chowed on hamburgers and swigged from plastic bottles of Ting, a sugary citrus soda popular in the Caribbean.

The debut 10-episode season airs this summer on Discovery Life, a cable channel that specializes in medical programming starring real people, like The Boy With No Brain and Untold Stories of the ER. Last year it drew an average of 88,000 viewers a night during prime time, according to Valeria Almada, a spokeswoman for the channel. That ranks around 97th among networks, by one recent estimate of viewership.

The shows primary sponsor is MannKind, an insulin manufacturer thats in bad financial shape. Neither the show nor the company would say how much the sponsorship cost, but MannKind willget advertising spots for its struggling insulin inhaler, Afrezza, during commercial breaks and perhaps a brief mention of the product on the show itself.

Mattocks makes a point of telling STAT that hes not promising anyone they can reverse their diabetes. But he has, in the past, said exactly that.

And one of the sponsors of his show expressly promised that, too on camera. The company, OneCare, makes software to help patients manage their diabetes. And in exchange for his $6,000 sponsorship, CEO Gary Austin got to film a segment on set in Jamaica in which he explains to the cast members how his product works and tells them it will help them vanquish diabetes. Its possible, he told them. You can reverse it.

Three of thepatients Mattocks recruited for the show are convinced.I truly believe that within the next year I will no longer be called a diabetic, said Lisa Campbell, cheerful and effortlessly expressive in her Southern drawl.

I truly believe that within the next year I will no longer be called a diabetic.

Lisa Campbell, cast member

At 54, she has a litany of health complaints so severe, they forced into retirement from her career as an elementary school teacher four years ago. Her right foot isswollen and her ankle deteriorated from complications ofdiabetic nerve damage, known as neuropathy. Her vision is so blurred by retinopathy that she recently went blind for four months. To get around her home near Atlanta, she juggles between a wheelchair, walker, and cane.

Her 49-year-old husband, Roger, who joined her on set, has also been ravaged by diabetes: His left leg was amputated a few inches below the knee in 2015 and shortly before the filming, hedbeen diagnosed with congestive heart failure. Hed also developed a wound on his stump, but didnt tell his doctor because he suspected hed get hospitalized and have to skipthe trip, his first ever out of the country. He refused to miss it.

For patients with such advanced conditions, the hope of vanquishing diseaseis often an unrealistic one. And criticsworryReversedwill add fuel to aflourishingcottage industry premised on the idea that diabetes can be reversed.

You can manage it. You can control it. You cant reverse it. All this talk about reversing diabetes is a huge load of BS, said David Kliff, who has type 1 diabetes and publishes the newsletter Diabetic Investor.

To be sure, diabetics, like everyone else, can only benefit from a healthy diet and exercise. But theres no cure for diabetes. Type 1 diabetics cant quit their medicine, ever. And its extremely difficult for type 2 diabetics to do so, barring bariatric surgery. More than 2,200 such patients went on an intense diet and exercise regimen for a studypublished in 2012; after one year, only 11.5 percent were able to get off their medicine or get their blood sugar levels down to a certain threshold. After four years, just 7 percent were still there.

The whole reversed idea is: run screaming from the meds, said Amy Tenderich, a vocal patient advocate with type 1 diabetes. She worries that it might send the wrong message that if you continue to need medication or have to go on insulin, that you have failed.

Rick Phillips, a blogger with type 1 diabetes, shares that concern. He wrote inablog postthat he saw the TV shows title as an affront,the latest in a line of rhetoric that blames diabetics for their own disease. He cited recent comments from White House budget director Mick Mulvaney suggesting that American taxpayers shouldnt have to pay for the health care of the person who sits home drinks sugary drinks, and doesnt exercise, and eats poorly, and gets diabetes.

Mattocks did not take kindly to Phillipss critique of his show. Instead, he jumped on Twitter to call Phillips irrelevant and a clown. He added: Go be miserable some other place.

Mattocks insists that his show demonstrates its possible to slow the progress of the disease by reversing the way patients live their lives. He brought ahandful of experts onto the set to dispensetips about healthy habits, like how to read nutritional labels on breakfast cereal and how to tell if blood sugar levels are in a safe range.

He also sought to effectively scare his stars straight.Cast memberswere taken on a day trip to a dialysis center and a diabetes clinic in Kingston, Jamaicas capital, where they gaped at local patients in the advanced stages of diabetes.

You can manage it. You can control it. You cant reverse it. All this talk about reversing diabetes is a huge load of BS.

David Kliff, publisher, Diabetic Investor

Then there wasthescene filmed on Day 6: Participants had toput on baggy jeans, a long belt, and a big checkered shirt using only one hand a challenge meant to show them what daily life is like for patients whove lost limbs due to complications from advanced diabetes.

Roll sound. And action!

Margie Rivera, a bubbly grandmother from Tampa, Fla., went first, though she hardly needed the exercise to introduce her to the debilitating effects of diabetes. She lost her job as a dialysis technician a year ago after diabetic retinopathy eroded her vision. Just before filming began, another blow: She and her husband lost the house they had been renting with intent to buy.

Now, Rivera, 53, used her teeth to get the big shirt on. The pants went on easily enough until she struggled to lace the belt through the belt loops. God, this is hard, she murmured.

Next up was Jerome Hughes, a 43-year-old former retail manager from Atlanta whos quick to crack jokes. He had the bright idea of lacing the belt through the pants before putting them on. But he struggled mightily to get the bulky denim up over his black high-top shoes. As he grew more and more frustrated, Mattocks put a supportive arm over his shoulder and stepped in to help. Hughes struggled some more with the shirt, never getting it fully on, until Mattocks marched him away from the cameras. Both of their faces were creased with emotion.

Everyone on this show has been reversed, Mattocks later told STAT. Mentally, physically, emotionally, and even spiritually in a sense.

Mattocks, 46, is the opposite of what youd expect Bob Marley to be like. Tightly wound and usually multitasking, Mattocks buzzes around his set, always intentional and in control. He talks in real life in much the same way he does on camera: in a quiet and soothing voice, peppering his speech with phraseslike healing and journey and changing lives.

Mattocks only met his famous uncle twice, in brief encounters as a child. But the reggae legend has been his inspiration to make a difference in this world, he said.

He started out as a rapper and actor, then turned to cooking, branding himself as The Poor Chef demonstratinghealthy meals that could be made for just $7.

Mattocks was diagnosed with type 2 diabetes at age 38. His doctor gave him no guidance about lifestyle changes, he said. But on his own, he was determined to turn his health around. He stopped bulking up in the gym. He started walking, and then running. He stayed away from fried foods. He lost about 20 pounds in 2 1/2months.

Once-promising diabetes breakthrough comes unglued with a major retraction

Mattocks never went on insulin, and spent just nine months on metformin before his doctor advised him he could stop, he said.

That led to yet another career pivot: He became an evangelist for managing diabetes.

To that end, he vouched foran energysupplement aimed at diabetics. He wrote a childrens bookabout a furry diabetic bear named Charlie B. Marley. At one point, he even created a sugar-free chocolate bar infused with coconut oil and called it the Charles Bar.

Mattocks, who lives in Tampa, was careful when he talked to STAT about his journey: He made clear that he has not reversed his own diabetes but simply has it under control. But hes been much more aggressive about dangling the promise of reversal in other public outreach.

What if I told you that you could reverse your diabetes? he wrote in a 2015 op-ed.

And in the trailer for his documentary The Diabetic You: We did it, he says, We proved that diet and exercise, lifestyle changes, you can reverse diabetes. Then he breaks down with emotion, hand over his eyes, as the screen turns to black.

His swaggering confidence in his ability to tame a chronic diseasecomes across especially clearly in the recently released first issue of his new Reversed Magazinefor diabetics. Hes listed as chief editor.

Its in large part a tribute to himself, an Oprah magazine with lower production standards and more self-flattery.

Mattocks poses on the cover wearing a cowboy hat, bandanna, and a big-buckled belt. The tagline: Theres a new sheriff in town. Under that: Charles Mattocks changes the face of diabetes. An article inside says we must admire Charles Mattocks.

There were no auditions for Reversed.Mattocks picked the five stars of his show by plucking out old friends and friends of friends with an eye toward appealing to a broad audience. (Shes going to be great for the Latin American community, he said of Rivera, who was born in Puerto Rico.)

In the spirit of marriage boot camp reality shows, the producers put the Campbells on camera together as much as possible.Theyre a match of opposites Lisa lively and talkative; Roger, quiet and concise and that dynamic was on display duringon-camera therapy sessions, trust exercises, and cooking scenes.

With cameras rolling and the on-set dietician murmuring encouragement, the couple tore kale into strips, sprinkled on some olive oil, and gently massaged the oil into the leaves during one such scene. Lisa chattered happily about how much she loves preparing kale chips. Roger, who used to manage a paint store before his worsening health put him on disability, dutifully lowered the pan layered with kale stripsinto the oven.

(That was acting. I made them just for the camera. I do not like them, he later confessed to STAT.)

The crew moved on to the next shoot helping Rivera prepare healthy ice cream made from frozen strawberries and bananas.

Then a producer jumped in. Theyd forgotten about the kale chips!

Sure enough, they were burning in the oven. Much of the batch was charred to a crisp.

The setting was undeniably gorgeous: Most of the show was filmed in a 14-bedroom villanestled in lush green hills, with aglistening turquoise swimming pool out backand, far below, the ocean.

Still, the filming wasnt always easy for the Campbells. After Lisa took a tumble walking up an outdoor ramp, she mostly stuck to a wheelchair on set. For his part, Roger had experienced an alarming low blood sugar episode on Day 2of filming. He was often claustrophobic and felt too hot to sleep. And he needed frequent breaks to smoke. (Mattocks and the others gently chastised him about his cigarettesbut never asked him to stop.)

Despite it all, both he and Lisa made it to the shows graduation ceremony in the nearby resort town of Negril, where they donned black caps and gowns to acceptcertificates of accomplishment.

Just before the cameras started rolling, a crew member spotted a problem: a telltale green bottle of Ting, resting on a ledge. Get that soda out of the shot! he bellowed.

Mattocks is betting big on Reversed. Hes funding the project in part with his own savings, though he wouldnt specify how much. The shows total budget is very low, he said. Its more of a work of love, you know what Im saying?

To help pay the bills, Mattocks secured a few sponsors, including the struggling pharma company MannKind.

It was an unusual fit, given that Mattocks has long been a self-described outspoken critic of drugcompanies and their advertising. And, indeed, despite the sponsorship, the vibe on the Reversed setwas markedly anti-pharmaceutical.For a few days of filming, Mattocks brought in a health coach (a doctor who doubles as a naturopath and uses his website tosell supplements) to work with the cast members.

Everyone on this show has been reversed mentally, physically, emotionally, and even spiritually in a sense.

Charles Mattocks, executive producer

The diabetic stars of the show spoke in often bitter terms about their distaste for the drug industry and their desire to get off drugs for good.

We are naturally getting ourselves weaned off of this insulin, Lisa Campbell confidently told STAT.

In phone interviews nearly two months after returning home, three ofthe participants said they were on their way to reversing their diabetes. (Hughes, for his part, said he thought in terms of reversing his mindset.) They raved about their double-digit weight loss, their new diets packed with vegetables, and their reduced need for insulin. They were undaunted by the long odds they face in their quest to restore their health, saying that the mentoring they got on the show would give them an edge.

Even Roger Campbell, who hasnt managed to cut all of his unhealthy habits, speaks with pride about his progress. Sure, hes still smoking cigarettes, but hes down to half a pack a day, compared to a full pack a day before filming. And, yes, he hasnt given up soda completely, but hes replaced his bottle of Diet Coke every other day with a Coke Zero once a week. He credits those and other changes with cutting in half his use of insulin.

I actually feel like I am reversing my diabetes, Roger Campbell said. I hope to eradicate it completely.

Yet many of the challenges that shape their lives are unchanged: Roger Campbells congestive heart failure makes it hard for him to do much exercise. Lisa Campbell still struggles to see clearly and cooks her (newly healthy) breakfasts from her wheelchair. And money is still painfully tight. The couple remains reliant on food banks, where fresh produce can be limited.

Mattockss team recently released an pathos-heavytrailer for Reversed,which debuts at 7 p.m. on July 18.

Theres Rivera honing her arm muscles by stretching a resistance band. Hughes meditates, his eyes closed and hands clasped. Lisa Campbell splashesin the swimming pool. Gloved hands clean theopen wound on Roger Campbells leg stump. The cast member who quitwalksout the front door.

Five lives came for HOPE, banner text reads. Five lives will NEVER be the same.

New diabetes tech is coming. But will it make much difference?

Mattocks is already planning a second season. Another producer said theyrethinking about setting it in Latin America this time. Especially if next season we have a bigger budget and a bigger crew and a different location, I think we can rival any show out there, Mattocks mused.

In the meantime, hes begun marketing a new offering: a diabetes getaway, branded as the Reversed retreat, in the Jamaican resort house where the show was filmed.

For a week in September (just before the season finale of Reversed), instructors will be on hand to guide vacationers through the many of the same exercises the cast carried out for the cameras: early morning yoga. A juicing workshop. Group meditation.

The cost: up to $4,000 for the week, for those who spring for a private suite.

Airfare is not included.

Rebecca Robbins can be reached at rebecca.robbins@statnews.com Follow Rebecca on Twitter @rebeccadrobbins

Originally posted here:
The Real World, Diabetes: As cameras roll, patients seek healing - STAT

Read More...

Tour de Cure raises money for diabetes prevention – NEWS10 ABC – NEWS10 ABC

Monday, June 5th, 2017

SARATOGA SPRINGS, N.Y. (NEWS10) Cyclists took over the Spa City today for the 2017 Saratoga Tour de Cure.

Its one of the biggest events in the Capital Region to raise awareness for diabetes, taking place at Saratoga State Park.

All these cyclists here to raise money for diabetes research, the heroes of the event are the ones donning red.

To get that many people out here to show support its just overwhelming, said Randy Lewis of Clifton Park.

For the past seven years, Type 1 diabetes patient, Lewis has biked in Saratogas Tour de Cure.

His family was there to cheer him on.

Two years ago, his youngest daughter joined him on the ride, when she too was diagnosed with the disease.

Even though Ive watched my dad for 24 years, grow up with this disease, I honestly thought my life was over, said Sydnie Lewis.

Around 1500 cyclists, some riding as far as 100 miles came to show support at the event.

This was an emotional day for the Red Riders, people who are biking with Type 1 or Type 2 diabetes.

Crossing the finish line the first time, I did it, I had tears in my eyes, said Red Rider, Jen Edmiston.

Ben Heidbreder, a 13-year old trained for months to bike 50 miles with his dad.

Very proud of him he raised over $2,300 for diabetes research. Hes a champion rider, said Jeff Heidbreder of his son.

The event is something Sydnie and her father look forward to every year.

A reminder that life can be a tough ride, but youre never alone.

Theres so many people around you whether have it or they know someone or they just know of the disease. You have a huge support group no matter where you go, said Sydnie Lewis.

The goal is to raise $1.1 million and all proceeds go towards mission of American Diabetes Association, to prevent and to cure diabetes.

Follow this link:
Tour de Cure raises money for diabetes prevention - NEWS10 ABC - NEWS10 ABC

Read More...

TPR Lifeline: Diabetes And Brittle Bones – Texas Public Radio

Monday, June 5th, 2017

Diabetics are at risk of many serious side effects like heart trouble, nerve damage, kidney failure, blindness and amputations. Now, theres growing evidence the disease also puts people at greater risk of bone fractures. In todays TPR Lifeline, Bioscience-Medicine reporter Wendy Rigby talks to Dr. Ajeya Joshi of South Texas Spinal Clinic about the link between diabetes and brittle bones. Here is a transcript of the interview.

Rigby: This will be news to many people that having diabetes puts you at greater risk of brittle bones. Dr. Joshi, whats happening here to increase the risk of osteoporosis in type one and type two diabetics?

Joshi: Diabetes can affect practically every organ in the body. But now we know that it impacts bone. And if you think about diabetes as having too much sugar floating around in your bloodstream, well the bones have blood flowing to them. And so that sugar lands inside the bone matrix and corrodes it, if you will. So its not that you necessarily have less bone, but the bone that you do have is not of a good quality.

Rigby: So even if you get a normal bone scan, if you have diabetes you might be more at risk than someone without diabetes of fracture.

Joshi: Thats absolutely right. So we know that for diabetics we have to interpret their bone scans differently. And thats an understanding that we didnt necessarily routinely have five or ten years ago. So they are at risk at fracturing at bone scores that would be considered normal for other people.

Rigby: And what part of the body is most affected?

Joshi: You could see fractures like a wrist fracture in a 50-year-old female tennis player that might have fallen on the tennis court. Vertebral fractures are common, of the spinal column if you will in many of us. An important metric to follow in any medical office is how tall is our adult patient. And you see people losing height over time and that might be very important. And the final area thats common are shoulders and hips as we get into our seventies and eighties.

Rigby: What could you do for someone whos diabetic if you knew or you could tell that they were developing this side effect from the disease?

Joshi: We need to now recalibrate or adjust how we think of diabetics and think of an earlier threshold for helping them with their bone density studies when theyre low. For our diabetic patients whether its avoiding vascular problems like heart disease or stroke or dialysis from kidney failure, controlling your sugars is important for one more reason.

Rigby: This paper you recently published used data from University Health System. Where was it published and what audience were you trying to reach with this particular message?

Joshi: We were excited to be involved in this research which was published in the Journal of Immigrant and Minority Health.

Rigby: What did you find in particular about Hispanic diabetics?

Joshi: Being both diabetic and Hispanic raised the risk of fracture above the population that was diabetic but not Hispanic by one-and-a-half to two times. And that makes us say weve got to pay particular attention to these patients, communicate with them, educate them and their primary doctors and in the future, dedicate more attention and resources to understanding the background behind that.

Rigby: So people who are listening to this and saying I might fall into that category may wonder what happens if I have this? Is there something that can be done for me so that I can keep my bones strong?

Joshi: I would say that if you fall into a category where youre diabetic or Hispanic and diabetic, the key takeaways are being aware and being very attuned to lifestyle, exercise, sugar control and knowing that this is one more reason to control your sugars. And weight-bearing exercise is incredibly important. So there are factors like exercise which the bones love. Our bones being loaded. So the astronauts in space lose bone mass because theres no gravity. So walking is a great and important way to help your bone mass.

Rigby: Do you think more research will be done on this topic?

Joshi: I expect that we will be seeing a lot more attention devoted to this area in the years to come.

Rigby: Dr. Joshi of the South Texas Spinal Clinic, thank you so much for joining us.

Joshi: Its a pleasure to be here. Thank you.

View original post here:
TPR Lifeline: Diabetes And Brittle Bones - Texas Public Radio

Read More...

Glen Cove Auto Show Raises Money For Diabetes Cure – CBS New York

Monday, June 5th, 2017

June 4, 2017 3:44 PM

GLEN COVE, N.Y. (CBSNewYork) Hundreds of car enthusiasts came to Glen Cove to check out an assortment of classic cars Sunday all to raise money for diabetes research.

As 1010 WINS Darius Radzius reported, Lamborghinis, Porsches and even a McLaren were on display at the Gold Coast Concours/Bimmerstock auto show.

If theres anything you can think of, they have it here, one visitor said. A lot of Porsches here; American cars.

Sergio Alvarezs cars a Porsche 918 Spider, and a McLaren P1 were attracting the most attention. But no one has asked to drive them.

Sit in it, thats about it, he said.

1010 WINS is a proud supporter of the event. Money raised will go to the Diabetes Research Institute.

CELEBRATING 50 YEARS

Get Our Morning Briefs

Bloomberg WCBS Tri-State Business Index

CBS 2

1010 WINS

WCBS Newsradio 880

WFAN Sportsradio 66/101.9

Contests & Promotions

About Us

Advertise

Business Development

Contact

Mobile

Connect

Only CBS

CBS Radio Jobs

CBS Television Jobs

CBS Television Public File

CBS Radio Public File

See more here:
Glen Cove Auto Show Raises Money For Diabetes Cure - CBS New York

Read More...

Mild-to-moderate obstructive sleep apnea is associated with hypertension, diabetes – Medical Xpress

Monday, June 5th, 2017

June 5, 2017 Illustration of obstruction of ventilation. Credit: Habib Mhenni / public domain

Preliminary data from two studies suggest that mild-to-moderate obstructive sleep apnea is associated with an increased risk of developing hypertension and diabetes.

"We found that even mild sleep apnea was strongly associated with increased risk of developing hypertension by 4 times compared to individuals without sleep apnea," said principal investigator and lead author Alexandros N. Vgontzas, MD, Professor in the Department of Psychiatry at Pennsylvania State University College of Medicine. "Similarly, moderate sleep apnea was associated with increased risk of developing diabetes by almost 3 times compared to individuals without sleep apnea."

Results also show that these associations were strongest in young and middle-aged adults.

"In young and middle-aged adults, our findings suggest that early detection and treatment of mild-to-moderate sleep apnea is warranted in order to prevent future cardiometabolic disease," said lead author and postdoctoral scholar Yun Li, MD. "Given the stronger association of sleep apnea with metabolic abnormalities in this age group, emphasis should be placed on yearly monitoring of indices of metabolic symptoms and lifestyle interventions, such as weight control, healthy diet, regular exercise, and stress management."

According to the American Academy of Sleep Medicine, nearly 30 million adults in the U.S. have obstructive sleep apnea, a chronic disease that involves the repeated collapse of the upper airway during sleep. Common warning signs include snoring and excessive daytime sleepiness. While previous research has established that severe sleep apnea increases the risk of hypertension and diabetes, data regarding mild-to-moderate sleep apnea were unclear.

Both studies involved the Penn State Adult Cohort, a random general population sample of 1,741 adults. Participants completed a detailed medical history interview at baseline and were evaluated in a sleep center during an overnight sleep study. Those without hypertension or diabetes at baseline were followed up after 10 years.

The research abstracts were published recently in an online supplement of the journal Sleep and will be presented Monday, June 5, and Wednesday, June 7, in Boston at SLEEP 2017, the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS), which is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society.

Explore further: Babies born to mothers with sleep apnea have higher risk of adverse neonatal outcomes

More information: Abstract Title: Moderate Obstructive Sleep Apnea is Associated with Incident Diabetes: A Longitudinal, Population-based Study Abstract ID: 0424 Presentation Date: Monday, June 5 Oral Presentation: 1:45 p.m. to 2 p.m., ballroom A Presenter: Yun Li, MD

Abstract Title: Mild-to-moderate Obstructive Sleep Apnea is Associated with Incident Hypertension: A Longitudinal, Population-based Study Abstract ID: 0426 Presentation Date: Wednesday, June 7 Oral Presentation: 10:20 a.m. to 10:35 a.m., ballroom C Presenter: Alexandros Vgontzas, MD

A new study is the first to demonstrate a higher risk of congenital anomalies and resuscitation at birth in newborns of mothers who have obstructive sleep apnea.

African Americans with sleep apnea and insomnia are rarely diagnosed with either problem, even when the severity of the two sleep disorders are likely to affect their health, according to new research presented at the ATS ...

Consistent with previous reports, poor sleep quality was linked with joint pain in a recent Arthritis Care & Research study of the general population, but the study found no association between obstructive sleep apnea and ...

New research published in Respirology suggests that sleep apnea may increase the risk of developing chronic kidney disease to a similar extent as hypertension.

In a study of patients with hypertension, those with resistant hypertensionmeaning that their blood pressure remained elevated despite concurrent use of three antihypertensive agents of different classeshad a higher ...

A new clinical practice guideline from the American Academy of Sleep Medicine establishes clinical practice recommendations for the diagnosis of obstructive sleep apnea in adults.

The cessation of breathing during sleep caused by enlarged tonsils is common in preschool-age children and can cause serious complications, but the methods normally used to diagnose the condition are subjective and unreliable. ...

(HealthDay)Millions of Americans battle bothersome nighttime conditions, such as sleep apnea or the need to get up frequently to urinate.

A study comparing children between 7 and 11 years of age who have moderate or severe obstructive sleep apnea to children the same age who slept normally, found significant reductions of gray matter - brain cells involved ...

Obstructive sleep apnea, which causes people to briefly stop breathing while asleep, affects an estimated 5 percent of the population, not including the many more who don't even realize they suffer from the disorder.

Unbalanced signaling by two molecules that regulate breathing leads to sleep apnea in mice and rats, researchers report in the Jan. 23, 2017, Proceedings of the National Academy of Sciences. They show, working with rodents, ...

A single bout of sleep apnea impacts the human body's ability to regulate blood pressure.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:
Mild-to-moderate obstructive sleep apnea is associated with hypertension, diabetes - Medical Xpress

Read More...

How Diabetes Is Transforming People Into Real-Life Cyborgs – Geek … – Geek

Monday, June 5th, 2017

Diabetes both type 1, which is an incurable autoimmune disorder, and type 2 which is a lifestyle disease that can be reversed or cured are among the fastest-growing diagnoses in the world. Left untreated, they can cause life-threatening conditions and death. So its not surprising that the medical establishment is pumping resources into new methods of management.

What makes them worthy of talking about here on Geek is that technology is playing a major role. Todays diabetic is often wired up with Bluetooth sensors and custom software that turn them into virtual cyborgs with an awareness of their body chemistry that normal people cant match.

Heres a quick rundown of diabetes if youre not familiar with the condition. When you eat food, its split into three basic categories: carbohydrates, fats, and proteins. Carbohydrates, which are found primarily in plant products, break down into a sugar called glucose in your digestive system. That glucose is turned into fuel to power your mind and muscles.

The body does that conversion with a hormone called insulin, which is produced by beta cells in the pancreas. Type 1 diabetics dont make it at all their immune system destroys those beta cells for an as yet unknown reason. Type 2 diabetics make it, but for some reason its less efficient at breaking down glucose into energy.

When the body cant break down glucose, it has to get energy from other places mostly fat, but nothing is safe. That leads to a state of ketosis, where acids released from fats build up. Those acids can cause a wide variety of nerve and tissue damage.

So the life of a diabetic is basically monitoring their carbohydrate intake and then injecting an appropriate amount of insulin, based on a series of complex mathematical formulas, to match it. Too little and they go into ketosis. Too much insulin can drop their blood sugar dangerously low, which can lead to comas and death. Its a delicate tightrope that they walk every day.

The last few decades have seen advances in diabetes treatment that will blow your mind. To put them into context, lets rewind 50 years or so to look at what treatment was like.

Back in the day, a diabetic would wake up every morning and pee into a test tube. Theyd then drop a tablet into it that would change color to tell them what range their blood sugar was in high, normal or low. Theyd then take a single injection of long-lasting time-release insulin that would do for the entire day and hope for the best. When they were done, theyd take the syringe, boil it on the stove to sterilize it and put it back for tomorrow.

Needless to say, the life expectancy for diabetics was pretty short. Without a way to detect highs or lows, their bodies were at the mercy of a variety of factors and many died.

So there were two problems facing diabetics: being able to monitor blood sugar and being able to deliver the appropriate amount of insulin, no more, no less.

Monitoring got easier with the invention of the fingerprick blood glucose monitor in 1981. A drop of blood is introduced to an enzyme, and then an electrical current is passed through it. The number of electrons the sample loses correlates to the amount of glucose present in the sample. This allowed for significantly more precision, delivering a numerical representation of the patients current blood sugar.

That was coupled with the development of faster-acting insulin, so diabetics could treat highs as they happened. The next wave of diabetes care required them to be a more active participant in their management, checking glucose throughout the day and making adjustments as needed. As cool as this was, technology was about to get involved in a big way.

Fingerprick glucose is accurate but requires the diabetic to go through a process every time they want to check (and only works when theyre awake). The threat of low blood sugars at night is a very real one, as glucose levels can drop quickly. An accidental scientific discovery in the mid-1990s helped change the lives of diabetics around the world.

Researchers were experimenting with the bodys cell fluid in the skin and discovered that it basically mirrors the blood glucose level with about a 15-minute delay. In 1999, MiniMed got FDA approval for the first continuous glucose monitor an electrode thats inserted into a diabetics skin that transmits a reading every five minutes without the need to draw blood. Now patients could get real-time feedback on their blood sugar throughout the day. Those early sensors were good for about three days before the bodys immune system rejected them, but modern ones can go for a week or more before theyre changed.

Monitoring that accurate is all well and good, but a diabetic would still need to give themselves an injection to bring high blood sugar down. However, an earlier invention made that process significantly easier. In 1973, Dean Kamen (inventor of the Segway) debuted the worlds first wearable insulin pump, a device that could dose any amount of insulin to a diabetic through a cannula, or small tube, that attached to the body. This gave diabetics even more control over their treatment, enabling them to microdose and control exactly how much of the hormone they receive.

Pumps have advanced significantly over the last decade, with one the Omnipod not needing a tube at all, but affixing directly to the skin and communicating wirelessly with a control device. Patients who manage diabetes with these devices are uniformly in better condition, and even though only one in a thousand diabetics currently uses a pump, that number is rising.

The next step is the artificial pancreas, a device that combines the two into one. These have passed clinical trials and are being rolled out slowly by endocrinologists around the country. Using complex algorithms, they monitor blood glucose and treat it at the same time in a closed-loop system, also administering glucose when blood sugars are too low. Early results are incredibly positive. Like existing pumps and CGMs, they still have to be changed out regularly, but the system marks a significant advance in treatment.

The future of diabetes is even more exciting. Companies are working on insulin that doesnt have to be injected, but rather is absorbed through the skin with a sound-activated patch. Another brand can be inhaled before a meal. Google is collaborating with contact lens manufacturer Alcon on a lens that measures blood sugar through the eye.

So if you see somebody walking around with some little gray boxes attached to their arms or stomach, its highly possible that theyre toting around a cyborg pancreas, wired into the cloud and keeping them healthy.

Read more from the original source:
How Diabetes Is Transforming People Into Real-Life Cyborgs - Geek ... - Geek

Read More...

Ask a Doc: At risk for diabetes? Simple lifestyle changes could save your life – AZCentral.com

Sunday, June 4th, 2017

Dr. Tiffany Pankow, Special for The Republic | azcentral.com 7:00 a.m. MT June 2, 2017

Dr. Tiffany Pankow(Photo: HonorHealth)

Question: What can I do to prevent becoming diabetic?

Answer: More than one in three Americans has prediabetes, and 90 percent of them dont know it.

With prediabetes, your blood sugar levels are impaired but arent high enough to be diagnosed as diabetes. Because most people dont have symptoms, it can go undetected without screening.

Unfortunately, many with this condition will develop diabetes within a short time if the condition isnt addressed.

If you have prediabetes, youre at increased risk for heart disease and stroke. If diabetes develops, add blindness, kidney failure, and loss of limb from amputation to the risk list.

The good news is that you often can prevent diabetes with healthy lifestyle modifications, education, and sometimes, medication.

Identifying the early stages of glucose impairment before diabetes develops is an important way to reverse and prevent chronic disease.

If you have one or more of the following risk factors, talk to your doctor about screening for prediabetes with a blood test:

If you have prediabetes or are at risk for developing diabetes, several lifestyle changes can greatly decrease your risk. Although making lifestyle changes can be challenging, even small adjustments can have lasting results:

Losing 5-7 percent of your body weight can prevent or delay the progression to diabetes.

Replacing processed and packaged food with vegetables, fruits and lean protein such as chicken, fish, and turkey improves nutrition and decreases calories.

Avoiding white flour in pasta, pastries and bagels and instead choosing whole-grain options for carbohydrates can improve blood sugar levels.

Increasing exercise to a goal of 150 minutes per week and getting enough restful sleep can also help lower glucose levels and prevent diabetes.

Managing stress is another important component of a healthy lifestyle.

Limiting added sugar in foods to 25 grams (6 teaspoons) a day for women and 37.5 grams (9 teaspoons) for men is an American Heart Association recommendation.

For more information or to find a doctor to help you with screening or treatment for prediabetes, visit honorhealth.com/medical-services/primary-care.

Tiffany Pankow, MD, specializes in family medicine with HonorHealth Medical Group. She can be reached at 480-882-7360 or visit https://www.honorhealth.com/physicians/tiffany-pankow

More Ask a Doc:

Can a hacker tinker with my ticker?

First psychotic episode? Seek early treatment

When large brain vessels shrink

This could be why your heel is hurting

Read or Share this story: http://azc.cc/2rN2Ui4

See the original post:
Ask a Doc: At risk for diabetes? Simple lifestyle changes could save your life - AZCentral.com

Read More...

Gastric Bypass Surgery May Be Best Bet for Diabetes – NBC 5 Dallas-Fort Worth

Sunday, June 4th, 2017

Diabetes can be deadly. Each year, more than 70,000 Americans die from complications of the disease. About half of all people with Type 2 diabetes don't have their condition under control.

New research now confirms a well-known procedure for weight loss may be the best bet for patients with uncontrolled diabetes.

Lisa Shaffer, at her heaviest, weighed nearly 300 pounds.

"When I was obese, my life was so limited," Shaffer said.

Her health suffered, too. Lisa had Type 2 diabetes, and she tried everything to control it.

"Nothing worked, nope," Shaffer explained.

But today she is 120 pounds lighter and her diabetes is gone. The reason: gastric bypass surgery.

"It's been incredible. Yeah, it really did give me my life back," Shaffer said.

Dr. Phillip Schauer, director of the Cleveland Clinic Bariatric and Metabolic Institute, led a study that compared bariatric surgery, either gastric bypass or gastric sleeve, to intense medical therapy in people with diabetes. After five years, the gastric bypass patients did the best. Many were in complete remission without drugs or insulin.

"Which is pretty remarkable. That's about as close to a cure that you can get," Schauer said.

Twenty-nine percent of gastric bypass and 23 percent of gastric sleeve patients achieved and maintained normal blood sugar levels, compared to just 5 percent of medication-only patients. The surgery groups also lost more weight and reported a better quality of life.

"All in all, the patients who had surgery did better and were happier at the five- year mark," Schauer said.

Three days after her surgery, Shaffer was off all of her meds. Her A1c, a measure of blood sugar control, was 10.5 before the surgery and today, it's 5.3. Now she's able to live the life she's always wanted.

"Ever since I lost the weight, I've run three 5Ks. I've done zip-lining with the family, which is fantastic. Just no limits anymore, there's no limitations on my life anymore," Shaffer said.

Schauer says weight loss is one reason diabetes patients benefit from bariatric surgery. The other is something that happens in the body as a result of the surgery. When the intestines are bypassed, special hormones increase, which helps the pancreas produce insulin more effectively.

Published at 4:48 PM CDT on Jun 2, 2017 | Updated at 4:55 PM CDT on Jun 2, 2017

Read more from the original source:
Gastric Bypass Surgery May Be Best Bet for Diabetes - NBC 5 Dallas-Fort Worth

Read More...

Page 51«..1020..50515253..6070..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick